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Eczema, the clinical phenotype of atopic eczema/dermatitis, affects around 20% of pre-school age 
children in the United Kingdom (UK).  The disease manifests during the first year of life in 60% but it 
can develop at any age.  It can have a significant psychosocial impact on the child and their family.  
While eczema improves or resolves in up to 70% of children, markers of persistence are early onset, 
severe disease, family history, and early allergen sensitisations.   
 
NICE guidance1 was published in 2007 and is due to be updated soon, as there have been important 
advances in our understanding of its treatment during this time.  The focus of this article is on 
children with eczema who have disease of mild or moderate severity, in whom diagnosis and 
management should be possible exclusively within primary care.  
Diagnosis  
Eczema is diagnosed clinically, the characteristic features being dry, rough and itchy skin.  Classically the scalp, cheeks and 
extensor surfaces are affected in infants; with flexural, especially the cubital and knee folds, involvement later, along with 







Table 1).  Seborrhoeic dermatitis is the most common differential diagnosis in infants, in which the 
lesions are early onset, greasy rather than dry, involve the scalp (cradle cap) and not itchy. 
Management 
The main principles of treatment are avoidance of trigger factors, maintenance of the epidermal 
barrier with emollients, and anti-inflammatory therapy with topical corticosteroids or calcineurin 
inhibitors.  Detergents, wool fabrics, extremes of temperature and humidity and psychological stress 
are all factors reported to contribute to eczema “flares”.  Emollients should be used daily and anti-
inflammatory treatments in step-up/down manner according to disease severity (Figure 1). 
 
Emollients 
Emollients can be used in three main ways: as a “leave on” treatment, soap substitute and/or bath 
additive. 
 
All patients should use emollients, as a “leave on” treatment – that is,  applying them directly to the 
skin and add or help retain moisture.  Used regularly, they improve the skin barrier, comfort and 
may reduce the number of disease flares.  Many different emollients can be prescribed or bought 
over-the-counter.  The main formulations are lotions, creams, gels and ointments, which vary in 
their consistency from “light” to “heavy”.  This mainly reflects differences in oil (lipid) to water 
ratios.  Some products also contain humectants which help retain moisture. 
 
There is poor evidence regarding the clinical effectiveness, adverse effects and cost-effectiveness of 
different products.2 3  This is reflected in the guidance issued by Clinical Commissioning Groups and 
Local Health Boards in England and Wales respectively, who have produced over 100 different 
emollient formularies that made conflicting recommendations about 109 different emollients.4  
Recent NHS England guidance (www.england.nhs.uk/wp-content/uploads/2017/11/items-which-
should-not-be-routinely-precscribed-in-pc-ccg-guidance.pdf) is clear in that while it discourages the 
prescribing of emollients for people with “mild dry skin” only, GPs should continue to prescribe them 
for people with eczema.  
 
Referring to your local formulary, start with emollients without fragrances, urea or antimicrobials, as 
these ingredients are more likely to cause irritation.  Initially, consider prescribing one or more 
emollients in 100g quantities as “testers”, making appropriate amounts (500 grams or millilitres) of 
the preferred emollient(s) available on repeat prescription thereafter.  Make allowance for extra 
supplies needed for nursery or school, and for different “homes” when the child’s parents don’t live 
together.  Give clear directions on their use (see Table 2).  You may need to prescribe different 
emollients for different purposes, e.g. an ointment from a tub as a leave-on treatment and a cream 
in a pump for use as a soap substitute. 
 
Bath additives are distinct from other emollients, as they are designed to poured into the bath and 
provide “passive” moisturisation.  The recently published BATHE trial evaluated their use in 483 
children (1-12 years) recruited from primary care.5  Participants were allocated to usual care or usual 
care plus bath additive with the primary outcome measured at 16 weeks.  Neither the primary 
outcome of patient-reported measure of eczema severity nor any of the secondary outcomes 
showed any benefit from the use of bath additives.  Consequently, mainly emollient guidelines no 
longer recommend their use, although it is possible that bath additives may still have a role in adults 






Topical corticosteroid and calcineurin inhibitors 
Topical corticosteroids (TCS) are all classified by their potency from mild through to very potent.  Examples are listed in 







Table 1: Clinical features of eczema 
• Pruritus 
• Xerosis  
• Typical morphology and age specific patterns 
- Facial, neck and extensor involvement in infants or children  
- Current or previous flexural lesions in any age-group  
- Sparing of the groin and axillary regions  
• Chronic or relapsing history  
• Atopy 
 
Table 2Table 3.  The choice of potency should be based on age, body site and severity of eczema.  
NICE’s recommendation of matching potency to severity (mild for mild, moderate for eczema, 
potent for severe) is easy to remember and apply, but without any evidence, such as how best to 
assess severity.6 
 
For most people with eczema, TCS are the only anti-inflammatory treatment needed, although 
topical calcineurin inhibitors may have a place for more severe disease and/or eczema in sensitive 
sites such as the face.  Topical pimecrolimus (Elidel) is licensed for mild to moderate eczema, and 
topical tacrolimus (Protopic) is licensed for moderate to severe eczema.  It is recommended that 
either are only initiated by a specialist/those experienced in managing the condition; and after 
failure of TCS and/or when there is the risk of TCS side-effects, particularly skin atrophy.  
 
Ointments are generally preferable to creams, unless the eczema is weeping or there is patient 
preference for creams.  TCS and CNI are most commonly used reactively to treat a disease flare, in 
which case a response to treatment should be expected in 7-14 days, with a view to stepping-down 
or stopping treatment thereafter.  However, some patients may benefit from proactive application 
of TCS on two consecutive days per week (“weekend therapy”) as a maintenance treatment of “hot 
spots”.7  
 
Patients and healthcare professionals worry about the risks associated with TCS use, which can be 
local (skin atrophy, striae and purpura) or systemic (hypothalamic pituitary axis and growth 
suppression).8  In fact, side effects are uncommon in clinical practice and patients may come to more 
harm from under-use rather than over-use.  While the quality and availability of data are limited, a 
recent review of 36 systematic reviews of TCS safety in people with eczema is reassuring.9  It found 
no significant differences in reports from individual short-term RCTs in the risk of developing skin 
atrophy with TCS compared to vehicle or between mild and potent TCS, and most trials reported no 
cases. The largest trial of TCS safety found only one case of skin atrophy in 1213 children followed up 
for 5 years. A meta-analysis of short-term observational studies in children showed a low overall rate 
of biochemical signs of adrenal suppression of 3.8% which decreased to 2% with mild potency 
topical corticosteroids. No clinical symptoms of adrenal insufficiency were observed and the 
biochemical changes were reversed upon stopping TCS.  Skin burning and pruritus are more common 
with topical calcineurin inhibitors than TCS.  However, the use of wet-wraps was found to 
significantly increased the rate of folliculitis; and there was a higher risk of local site reactions with 
topical calcineurin inhibitors compared to TCS and with TCS compared to Chinese herbal medicine.   
 
 
Risks can be minimised by considering the key factors that affect TCS absorption (Table 4).  Long-
term treatment, higher potencies, vulnerable sites, use of occlusion and/or extremes of age all 
increase the potential for harm.  The finger-tip unit (FTU) is a practical way of guiding the amount to 
be used: the amount of TCS that is squeezed out from the very end of the finger to the first crease in 




flat of the hand with the fingers together.  Once daily application of TCS is as effective as twice daily, 
minimises the risk of adverse effects and simplifies treatment regimes.10  Appropriate use of TCS 
minimises the risk of TCS withdrawal, data on which is very limited. 
 
Other treatments 
Despite the clear association between eczema and Staphylococcus aureus on the skin, there is 
uncertainty about what constitutes infection and when antibiotic treatments are likely to confer 
benefit.11  There is no clear evidence that anti-staphylococcal interventions such as antiseptic bath 
additive, or the addition of antimicrobial agents to topical therapies, are clinically beneficial in non-
infected eczema.  The CREAM trial, which randomised 113 children with clinically infected eczema 
flares, found no meaningful benefit from oral or topical antibiotics over placebo.12  Instead, 
stepping-up TCS may be a more helpful approach in this situation. 
 
Specialist clothing manufacturers claim benefits for the management of eczema, by helping regulate 
humidity and temperature, and possibly through an antimicrobial action.  The CLOTHES trial found 
no evidence of any difference between the 300 children randomised to receive silk garments and 
standard eczema care alone.  While this does not preclude parents from purchasing such garments 
themselves, the findings argue strongly against them being prescribed on the NHS. 
 
While some guidelines suggest use of sedating, first‐generation oral antihistamines when eczema 
causes sleep disturbance, for most children they have no role.  Oral corticosteroids should be 
avoided in all but the most severe exacerbations, in which case specialist input is warranted. 
Overcoming treatment barriers 
Treatment should be guided by disease severity and carer and older children’s preferences, 
especially with respect to emollients where acceptability may be influenced by severity, body site, 
season/climate and cultural beliefs.  Recent research has highlighted the importance of identifying 
and addressing parent’s concerns, which can otherwise lead to poor treatment adherence and 
outcomes.13  A common but sometimes unvoiced concern is diet in the affected child and/or the 
breast-feeding mother.  While immediate-type food allergies are more common, evidence that foods 
such as mild, egg or wheat cause the on-going symptoms of eczema in most children is weak.  The 
role of allergy tests is also controversial and subject to a feasibility trial.14  There is some evidence 
that probiotics taken during late pregnancy and breastfeeding (36 to 38 weeks gestation through the 
first 3 to 6 months of lactation) may reduce risk of eczema in offspring.15 
 
Evaluating disease severity in psychosocial as well as physical terms; acknowledging the challenges of using topical 
therapies long-term; and emphasising the “control not cure” message can all help.  However, even relatively simple 
treatment regimens can be difficult to follow, so aiming for “two treatment [emollient and TCS] used well”, backed-up by a 
Written Action Plan (Figure 2, www.bristol.ac.uk/ewap) with links to further information and online videos, may support 
self-management.16 17  The ECO programme (https://www.nottingham.ac.uk/eco/about-the-research/about-the-
research.aspx) is currently developing and evaluating a website to help people look after children with eczema, but 
meanwhile there are plenty of sources of reliable information available from eczema support groups (Figure 2: Eczema 










Table 1Table 5). 
Conclusions 
Although most children with eczema have mild-moderate disease, the impact and challenges of 
managing the condition should not be underestimated.  Two treatments (emollients and topical 
corticosteroids) used well can control eczema symptoms for the majority.  The focus for emollients 
should be finding one or more “simple” types that parent and child are willing to use daily as “leave 
on” treatment.  For topical corticosteroids, concerns about safety should be addressed and potency 
matched to site and severity of disease.  Supporting information, such as in the form of a written 
action plan, can help support families in knowing what to use where and when; and well as helping 
address some of the practical day-to-day issues such as swimming, use of sunscreens and 
nurse/school attendance.  If despite this disease control is poor, then referral to a community or 
hospital dermatology clinic should be made for further advice and potentially specialist treatment. 
Tables and Figures 
Figure 1: Eczema treatment escalator 
 
Adapted from NICE (2007) 
 










Table 1: Clinical features of eczema 
• Pruritus 
• Xerosis  
• Typical morphology and age specific patterns 
- Facial, neck and extensor involvement in infants or children  
- Current or previous flexural lesions in any age-group  
- Sparing of the groin and axillary regions  
• Chronic or relapsing history  
• Atopy 
 
Table 2: Emollient application 
• Wash hands 
• With pots, spoon the emollient out and replace the lid (to reduce the risk of infection) 
• Apply using downward strokes, allowing it to soak in (rather than rubbing). 
• Allow up to 60 minutes between application of emollient and topical corticosteroids or 
calcineurin inhibitors (to avoid dilution effects) 
 
Table 3: Examples of different potencies of topical corticosteroid 
Potency Examples 
Mild Hydrocortisone 0.1%, 0.5%, 1.0%, and 2.5%  
Moderate Betamethasone valerate 0.025% (Betnovate-RD®) and clobetasone butyrate 0.05% 
(Eumovate®) 




Clobetasol propionate 0.05% (Dermovate®) and diflucortolone valerate 0.3% 
(Nerisone Forte®) 
 
Table 4: Factors to consider in the safe prescribing of topical corticosteroids 
• Age 
• Area of the skin being treated 
• Duration of treatment 
• Potency of the topical corticosteroid 
• Occlusion 
 
Table 5: Sources of further information and advice for people with eczema 
• National Eczema Society – 0800 089 1122 or www.eczema.org 
• Eczema Outreach Support – 0800 622 6018 or www.eos.org.uk 
• Nottingham Support Group for Carers of Children with Eczema – 
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